{"Symbol": "APGE", "AssetType": "Common Stock", "Name": "Apogee Therapeutics, Inc. Common Stock", "Description": "Apogee Therapeutics, Inc., through its subsidiary, is a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company is headquartered in Waltham, Massachusetts.", "CIK": "1974640", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "BUILDING 17, WALTHAM, MA, UNITED STATES, 02453", "OfficialSite": "https://www.apogeetherapeutics.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "4630745000", "EBITDA": "-282332000", "PERatio": "None", "PEGRatio": "None", "BookValue": "9.88", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-4.38", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-0.253", "ReturnOnEquityTTM": "-0.384", "RevenueTTM": "0", "GrossProfitTTM": "0", "DilutedEPSTTM": "-4.38", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "104.29", "AnalystRatingStrongBuy": "0", "AnalystRatingBuy": "14", "AnalystRatingHold": "2", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "-", "PriceToBookRatio": "7.89", "EVToRevenue": "-", "EVToEBITDA": "-", "Beta": "1.426", "52WeekHigh": "84.56", "52WeekLow": "26.2", "50DayMovingAverage": "74.24", "200DayMovingAverage": "51.68", "SharesOutstanding": "54834000", "SharesFloat": "50475000", "PercentInsiders": "6.130", "PercentInstitutions": "116.144", "DividendDate": "None", "ExDividendDate": "None"}